Dosing and Administration | BYDUREON BCise® (exenatide extended-release) injectable suspension 2 mg | For HCPs
![Bydureon Bcise (Exenatide Extended-Release Injectable Suspension): Uses, Dosage, Side Effects, Interactions, Warning Bydureon Bcise (Exenatide Extended-Release Injectable Suspension): Uses, Dosage, Side Effects, Interactions, Warning](https://images.rxlist.com/images/rxlist/bydureon-bcise14.gif)
Bydureon Bcise (Exenatide Extended-Release Injectable Suspension): Uses, Dosage, Side Effects, Interactions, Warning
![Bydureon Bcise (Exenatide Extended-Release Injectable Suspension): Uses, Dosage, Side Effects, Interactions, Warning Bydureon Bcise (Exenatide Extended-Release Injectable Suspension): Uses, Dosage, Side Effects, Interactions, Warning](https://images.rxlist.com/images/rxlist/bydureon-bcise3.gif)
Bydureon Bcise (Exenatide Extended-Release Injectable Suspension): Uses, Dosage, Side Effects, Interactions, Warning
![BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older | Business Wire BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older | Business Wire](https://mms.businesswire.com/media/20210723005083/en/484259/22/Logo.jpg)
BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older | Business Wire
![Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon | Scientific Reports Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-53356-2/MediaObjects/41598_2019_53356_Fig1_HTML.png)